|
SATELLITE SYMPOSIA
|
|
Saturday 29 August 2009
|
|
12:00 - 13:30
|
|
|
v Anticoagulant therapy in acute coronary syndrome (ACS): confronting practical realities
|
Athens
|
Zone 4
|
|
Satellite Symposium organised by sanofi-aventis
|
|
|
v Cardiac computed tomography, refinement in diagnostics and beyond
|
Bucharest
|
|
Satellite Symposium organised by Toshiba Medical Systems Europe BV
|
|
|
v Recent Therapeutic Developments in the Field of pulmonary arterial hypertension
|
Stockholm
|
|
Satellite Symposium organised by Eli Lilly and Company
|
|
14:00-15:30
|
|
|
v Making the right choice for cardiovascular protection
|
London & The Hague
|
Zone 3
|
|
Satellite Symposium organised by Servier
|
|
|
v New perspectives in long-term anticoagulation: an innovative approach to improve patient management
|
Athens
|
Zone 4
|
|
Satellite Symposium organised by sanofi-aventis
|
|
|
v 2D and 3D wall motion tracking: experiences on left ventricular function
|
Bucharest
|
|
Satellite Symposium organised by Toshiba Medical Systems Europe BV
|
|
14:30-16:00
|
|
|
v Study concepts and routes of administration in autolgous stem cell therapy
|
Berne
|
Zone 1
|
|
Satellite Symposium organised by Miltenyi Biotec GmbH
|
|
|
v For the at-risk acute coronary syndrome (ACS) patient: the era of triple antiplatelet therapy
|
Damascus
|
|
Satellite Symposium organised by theheart.org and Iroko Pharmaceuticals
|
|
|
v Innovative heart failure management: from diagnosis to therapy
|
Helsinki
|
|
Satellite Symposium organised by Siemens Healthcare Sector and Medtronic
|
|
|
v Emerging evidence in the management of post-myocardial infarction patients with heart failure: understanding the effects of Aldosterone blockade
|
Tel Aviv
|
|
Satellite Symposium organised by Pfizer Inc.
|
|
|
v What more can we achieve beyond mono and combination therapy for hypertension management
|
Belgrade
|
Zone 4
|
|
Satellite Symposium organised by Bayer Schering Pharma AG
|
|
|
v Getting high risk patients to aggressive low-density lipoprotein-C goals with combination therapy
|
Budapest
|
|
Satellite Symposium organised by MSD/ Schering-Plough Pharmaceuticals
|
|
|
v From challenges to solutions in hypertension
|
Cairo
|
Zone 6
|
|
Satellite Symposium organised by Daiichi Sankyo Europe GmbH / Menarini International
|
|
|
v Latest advances in 2D and live 3D echocardiograpy
|
Moscow
|
|
Satellite Symposium organised by Philips Healthcare
|
|
|
v Evolving treatment goals in hypertension and heart failure: role of the angiotensin receptor blockers (ARBs)
|
Oslo
|
|
Satellite Symposium organised by Takeda Pharmaceuticals Europe Ltd.
|
|
|
|
|
|
Sunday 30 August 2009
|
|
12:45 - 13:30
|
|
|
v Heart rate, a new target in coronary artery disease
|
Rome
|
Zone 3
|
|
Satellite Symposium organised by Servier
|
|
|
v Breaking ground in atrial fibrillation: New strategies to reduce vascular events
|
Athens
|
Zone 4
|
|
Satellite Symposium organised by sanofi-aventis and Bristol-Myers Squibb
|
|
|
v Growing evidence of the last generation angiotensin-converting enzyme-inhibition to protect against cardiovascular disease
|
Belgrade
|
|
Satellite Symposium organised by Menarini International
|
|
|
v 3 in 1 combinations: a new frontier in hypertension management
|
Warsaw
|
|
Satellite Symposium organised by Novartis Pharma AG
|
|
|
v Redefining the treatment goals in pulmonary arterial hypertension: case-based learning
|
Prague
|
Zone 6
|
|
Satellite Symposium organised by Pfizer Inc
|
|
|
|
|
|
Monday 31 August 2009
|
|
18:30 - 20:00
|
|
|
v Heart and mind decision in the treatment of hypertention: eprosartan
|
Berne
|
Zone 1
|
|
Satellite Symposium organised by Solvay Pharmaceuticals GmbH
|
|
|
v C-Cure: from 1st to 2nd generation cardiac regenerative therapies
|
Damascus
|
|
Satellite Symposium organised by Cardio3 BioSciences
|
|
|
v Management of cardiovascular diseases: defiining current challenges and future options
|
Helsinki
|
|
Satellite Symposium organised by Merck Serono, a division of Merck KGaA
|
|
|
v Thrombosis management in cardiology: the relevance of direct Factor Xa inhibition
|
Sofia
|
|
Satellite Symposium organised by Bayer Schering Pharma AG
|
|
|
v Echocardiography in heart failure
|
Tel Aviv
|
|
Satellite Symposium organised by GE Healthcare
|
|
|
v Stroke prevention in atrial fibrillation: late-breaking insights from the RE-LY trial
|
Barcelona
|
Zone 2
|
|
Satellite Symposium organised by Boehringer Ingelheim GmbH
|
|
|
v A new concept in stroke prevention
|
London & The Hague
|
Zone 3
|
|
Satellite Symposium organised by Servier
|
|
|
v Redefining the therapeutic goals of atrial fibrillation: the time is now!
|
Rome
|
|
Satellite Symposium organised by sanofi-aventis
|
|
|
v The novel agent to support symptomatic stable angina patients in maintening their quality of life
|
Athens
|
Zone 4
|
|
Satellite Symposium organised by Menarini International
|
|
|
v Living with PAH - Challenges and Options
|
Belgrade
|
|
Satellite Symposium organised by GlaxoSmithKline
|
|
|
v Plaque vulnerability and the spectrum of coronary heart disease risk: differences between acute and chronic disease
|
Brussels
|
|
Satellite Symposium organised by GlaxoSmithKline
|
|
|
v Optimal use of dual antiplatelet therapy
|
Budapest
|
|
Satellite Symposium organised by Daiichi Sankyo Europe GmbH / Eli Lilly and Company
|
|
|
v The Responsible Gatekeeper: Is referral for percutaneous coronary intervention appropriate after SYNTAX or COURAGE or in women?
|
Stockholm
|
|
Satellite Symposium organised by Abbott Vascular
|
|
|
v Exploring cardio-renal protection through direct renin inhibition - An innovative approach to cardiovascular risk management
|
Warsaw
|
|
Satellite Symposium organised by Novartis Pharma AG
|
|
|
v Diagnosing and treating chronic thromboembolic pulmonary hypertension (CTEPH) now and in future
|
Oslo
|
Zone 6
|
|
Satellite Symposium organised by Bayer Schering Pharma AG
|
|
|
v Optimizing the antithrombotic risk-benefit profile for percutaneous coronary intervention
|
Prague
|
|
Satellite Symposium organised by The Medicines Company
|
|
|
|
|
|
Tuesday 01 September 2009
|
|
14:00 - 15:30
|
|
|
v Transcatheter Aortic Valve Implantation (TAVI) - A new treatment modallity for high risk aortic stenosis patients
|
Ankara
|
Zone 1
|
|
Satellite Symposium organised by Edwards Lifesciences
|
|
|
v Smoking the ignored risk factor: the elephant in the room
|
Berne
|
|
Satellite Symposium organised by Pfizer Inc.
|
|
|
v Old standard or gold standard? Re-evaluating the use of glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors in high-risk acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI)
|
Damascus
|
|
Satellite Symposium organised by Eli Lilly and Company
|
|
|
v Pushing the frontiers in cardiology
|
Helsinki
|
|
Satellite Symposium organised by Siemens Healthcare Sector
|
|
|
v Highly purified omega-3 fatty acid ehyl-esters: proven effects and future prospects
|
Tel Aviv
|
|
Satellite Symposium organised by Solvay Pharmaceuticals GmbH
|
|
|
v Ivabradine: revisiting the management of coronary artery disease patients
|
London & The Hague
|
Zone 3
|
|
Satellite Symposium organised by Servier
|
|
|
v Tackling complex coronary disease anno 2009: scientific and technological progress
|
Belgrade
|
Zone 4
|
|
Satellite Symposium organised by Boston Scientific
|
|
|
v Tackling hypertension and its chain reaction
|
Budapest
|
|
Satellite Symposium organised by Daiichi Sankyo Europe GmbH / Menarini International
|
|
|
v Diabetes and the heart: state-of-the-art treatement strategies
|
Brussels
|
|
Satellite Symposium organised by Munich Diabetes Research Institute and Diabetes & Cardiovascular Disease EASD Study Group
|
|
|
v Managing disease progression across the cardiovascular continuum: the role of angiotensin receptor blockers
|
Warsaw
|
|
Satellite Symposium organised by Bristol-Myers SquIbb and sanofi-aventis
|
|
|
v New advances in the management of atrial fibrillation: focus on cardioversion with atrial-selective therapies
|
Cairo
|
Zone 6
|
|
Satellite Symposium organised by Merck Sharp & Dohme
|
|
|
v The clinical impact of cardiovascular biomarkers in medicine
|
Vienna
|
|
Satellite Symposium organised by Inverness Medical
|
|
|
v New horizons in nuclear cardiology
|
Moscow
|
|
Satellite Symposium organised by GE Healthcare
|
|
|
v Pitavastatin: the simple and effective approach to lipid management in cardiovascular risk
|
Oslo
|
|
Satellite Symposium organised by Recordati Spa / Kowa
|
|
|
v Current perceptions of aspirin and cardiovascular disease prevention
|
Prague
|
|
Satellite Symposium organised by Bayer Schering Pharma AG
|
|
|
v Cardiovascular protection at the forefront of hypertension management
|
Madrid
|
|
Satellite Symposium organised by Boehringer Ingelheim GmbH
|
|
16:00 - 17:30
|
|
|
v Management of high-risk patients with type 2 diabetes - A collaborative approach
|
Berlin
|
Zone 3
|
|
Satellite Symposium organised by Bristol-Myers SquIbb and AstraZeneca
|
|
|
v Antiplatelets in the management of acute coronary syndromes and beyond: evidence and experience
|
Warsaw
|
Zone 4
|
|
Satellite Symposium organised by sanofi-aventis and Bristol-Myers SquIbb
|
|
|
|
|
|
|
|
|
v Latest strategies, organizational aspects and patient outcome in th treatment of the ST-elevation myocardial infarction.
|
Belgrade
|
|
Satellite Symposium organised by Boehringer Ingelheim GmbH
|
|
|
v Comprehensive lipid management: an evolving atherosclerosis treatment paradigm
|
Cairo
|
|
|
Satellite Symposium organised by Merck Sharp & Dohme
|
|
16:30 - 18:00
|
|
|
v Stroke prevention in atrial fibrillation: can we do better?
|
Tel Aviv
|
Zone 1
|
|
Satellite Symposium organised by Bristol-Myers Squibb Co. and Pfizer, Inc.
|
|
|
v Latest strategies, organisational aspects and patient outcome in the treatment of the ST-elevation myocardial infarction.
|
Belgrade
|
Zone 4
|
|
Satellite Symposium organised by Boehringer Ingelheim GmbH
|
|
|
v NYHA functional class II: an achievable goal for all patients with pulmonary arterial hypertension receiving treatment?
|
Bucharest
|
|
Satellite Symposium organised by Actelion Pharmaceuticals
|
|
|
v Lipid-related residual risk: the new millennium challenge
|
Prague
|
Zone 6
|
|
Satellite Symposium organised by R3i Organisation
|
|
|
|
|
|